Translational biomarkers of neurotoxicity

A health and environmental sciences institute perspective on the way forward

Ruth A. Roberts, Michael Aschner, David Calligaro, Tomas R. Guilarte, Joseph P. Hanig, David W. Herr, Thomas J. Hudzik, Andreas Jeromin, Mary J. Kallman, Serguei Liachenko, James J. Lynch, Diane B. Miller, Virginia C. Moser, James P. O'Callaghan, William Slikker, Merle G. Paule

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Neurotoxicity has been linked to a number of common drugs and chemicals, yet efficient and accurate methods to detect it are lacking. There is a need for more sensitive and specific biomarkers of neurotoxicity that can help diagnose and predict neurotoxicity that are relevant across animal models and translational from nonclinical to clinical data. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling compared with tissues. Increasing evidence supports the potential utility of fluid-based biomarkers of neurotoxicity such as microRNAs, F2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers such as those in CSF require invasive sampling or are specific to one disease such as Alzheimer's, while others require further validation. Additionally, neuroimaging methodologies, including magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission tomography, may also serve as potential biomarkers and have several advantages including being minimally invasive. The development of biomarkers of neurotoxicity is a goal shared by scientists across academia, government, and industry and is an ideal topic to be addressed via the Health and Environmental Sciences Institute (HESI) framework which provides a forum to collaborate on key challenging scientific topics. Here we utilize the HESI framework to propose a consensus on the relative potential of currently described biomarkers of neurotoxicity to assess utility of the selected biomarkers using a nonclinical model.

Original languageEnglish (US)
Article numberkfv188
Pages (from-to)332-340
Number of pages9
JournalToxicological Sciences
Volume148
Issue number2
DOIs
StatePublished - Dec 1 2015

Fingerprint

Environmental Health
Biomarkers
Health
Cerebrospinal fluid
Cerebrospinal Fluid
Ubiquitin Thiolesterase
F2-Isoprostanes
Magnetic resonance spectroscopy
Neuroimaging
Sampling
Positron emission tomography
Microtubule-Associated Proteins
Myelin Basic Protein
Fluids
Glial Fibrillary Acidic Protein
Magnetic resonance
Protein C
MicroRNAs
Positron-Emission Tomography
Industry

Keywords

  • Biomarker
  • CSF
  • Imaging
  • Neurotoxicity
  • Neurotoxicity

ASJC Scopus subject areas

  • Toxicology

Cite this

Roberts, R. A., Aschner, M., Calligaro, D., Guilarte, T. R., Hanig, J. P., Herr, D. W., ... Paule, M. G. (2015). Translational biomarkers of neurotoxicity: A health and environmental sciences institute perspective on the way forward. Toxicological Sciences, 148(2), 332-340. [kfv188]. https://doi.org/10.1093/toxsci/kfv188

Translational biomarkers of neurotoxicity : A health and environmental sciences institute perspective on the way forward. / Roberts, Ruth A.; Aschner, Michael; Calligaro, David; Guilarte, Tomas R.; Hanig, Joseph P.; Herr, David W.; Hudzik, Thomas J.; Jeromin, Andreas; Kallman, Mary J.; Liachenko, Serguei; Lynch, James J.; Miller, Diane B.; Moser, Virginia C.; O'Callaghan, James P.; Slikker, William; Paule, Merle G.

In: Toxicological Sciences, Vol. 148, No. 2, kfv188, 01.12.2015, p. 332-340.

Research output: Contribution to journalArticle

Roberts, RA, Aschner, M, Calligaro, D, Guilarte, TR, Hanig, JP, Herr, DW, Hudzik, TJ, Jeromin, A, Kallman, MJ, Liachenko, S, Lynch, JJ, Miller, DB, Moser, VC, O'Callaghan, JP, Slikker, W & Paule, MG 2015, 'Translational biomarkers of neurotoxicity: A health and environmental sciences institute perspective on the way forward', Toxicological Sciences, vol. 148, no. 2, kfv188, pp. 332-340. https://doi.org/10.1093/toxsci/kfv188
Roberts, Ruth A. ; Aschner, Michael ; Calligaro, David ; Guilarte, Tomas R. ; Hanig, Joseph P. ; Herr, David W. ; Hudzik, Thomas J. ; Jeromin, Andreas ; Kallman, Mary J. ; Liachenko, Serguei ; Lynch, James J. ; Miller, Diane B. ; Moser, Virginia C. ; O'Callaghan, James P. ; Slikker, William ; Paule, Merle G. / Translational biomarkers of neurotoxicity : A health and environmental sciences institute perspective on the way forward. In: Toxicological Sciences. 2015 ; Vol. 148, No. 2. pp. 332-340.
@article{aa8c4b9d66b944949642e97ce7c040e4,
title = "Translational biomarkers of neurotoxicity: A health and environmental sciences institute perspective on the way forward",
abstract = "Neurotoxicity has been linked to a number of common drugs and chemicals, yet efficient and accurate methods to detect it are lacking. There is a need for more sensitive and specific biomarkers of neurotoxicity that can help diagnose and predict neurotoxicity that are relevant across animal models and translational from nonclinical to clinical data. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling compared with tissues. Increasing evidence supports the potential utility of fluid-based biomarkers of neurotoxicity such as microRNAs, F2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers such as those in CSF require invasive sampling or are specific to one disease such as Alzheimer's, while others require further validation. Additionally, neuroimaging methodologies, including magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission tomography, may also serve as potential biomarkers and have several advantages including being minimally invasive. The development of biomarkers of neurotoxicity is a goal shared by scientists across academia, government, and industry and is an ideal topic to be addressed via the Health and Environmental Sciences Institute (HESI) framework which provides a forum to collaborate on key challenging scientific topics. Here we utilize the HESI framework to propose a consensus on the relative potential of currently described biomarkers of neurotoxicity to assess utility of the selected biomarkers using a nonclinical model.",
keywords = "Biomarker, CSF, Imaging, Neurotoxicity, Neurotoxicity",
author = "Roberts, {Ruth A.} and Michael Aschner and David Calligaro and Guilarte, {Tomas R.} and Hanig, {Joseph P.} and Herr, {David W.} and Hudzik, {Thomas J.} and Andreas Jeromin and Kallman, {Mary J.} and Serguei Liachenko and Lynch, {James J.} and Miller, {Diane B.} and Moser, {Virginia C.} and O'Callaghan, {James P.} and William Slikker and Paule, {Merle G.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1093/toxsci/kfv188",
language = "English (US)",
volume = "148",
pages = "332--340",
journal = "Toxicological Sciences",
issn = "1096-6080",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Translational biomarkers of neurotoxicity

T2 - A health and environmental sciences institute perspective on the way forward

AU - Roberts, Ruth A.

AU - Aschner, Michael

AU - Calligaro, David

AU - Guilarte, Tomas R.

AU - Hanig, Joseph P.

AU - Herr, David W.

AU - Hudzik, Thomas J.

AU - Jeromin, Andreas

AU - Kallman, Mary J.

AU - Liachenko, Serguei

AU - Lynch, James J.

AU - Miller, Diane B.

AU - Moser, Virginia C.

AU - O'Callaghan, James P.

AU - Slikker, William

AU - Paule, Merle G.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Neurotoxicity has been linked to a number of common drugs and chemicals, yet efficient and accurate methods to detect it are lacking. There is a need for more sensitive and specific biomarkers of neurotoxicity that can help diagnose and predict neurotoxicity that are relevant across animal models and translational from nonclinical to clinical data. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling compared with tissues. Increasing evidence supports the potential utility of fluid-based biomarkers of neurotoxicity such as microRNAs, F2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers such as those in CSF require invasive sampling or are specific to one disease such as Alzheimer's, while others require further validation. Additionally, neuroimaging methodologies, including magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission tomography, may also serve as potential biomarkers and have several advantages including being minimally invasive. The development of biomarkers of neurotoxicity is a goal shared by scientists across academia, government, and industry and is an ideal topic to be addressed via the Health and Environmental Sciences Institute (HESI) framework which provides a forum to collaborate on key challenging scientific topics. Here we utilize the HESI framework to propose a consensus on the relative potential of currently described biomarkers of neurotoxicity to assess utility of the selected biomarkers using a nonclinical model.

AB - Neurotoxicity has been linked to a number of common drugs and chemicals, yet efficient and accurate methods to detect it are lacking. There is a need for more sensitive and specific biomarkers of neurotoxicity that can help diagnose and predict neurotoxicity that are relevant across animal models and translational from nonclinical to clinical data. Fluid-based biomarkers such as those found in serum, plasma, urine, and cerebrospinal fluid (CSF) have great potential due to the relative ease of sampling compared with tissues. Increasing evidence supports the potential utility of fluid-based biomarkers of neurotoxicity such as microRNAs, F2-isoprostanes, translocator protein, glial fibrillary acidic protein, ubiquitin C-terminal hydrolase L1, myelin basic protein, microtubule-associated protein-2, and total tau. However, some of these biomarkers such as those in CSF require invasive sampling or are specific to one disease such as Alzheimer's, while others require further validation. Additionally, neuroimaging methodologies, including magnetic resonance imaging, magnetic resonance spectroscopy, and positron emission tomography, may also serve as potential biomarkers and have several advantages including being minimally invasive. The development of biomarkers of neurotoxicity is a goal shared by scientists across academia, government, and industry and is an ideal topic to be addressed via the Health and Environmental Sciences Institute (HESI) framework which provides a forum to collaborate on key challenging scientific topics. Here we utilize the HESI framework to propose a consensus on the relative potential of currently described biomarkers of neurotoxicity to assess utility of the selected biomarkers using a nonclinical model.

KW - Biomarker

KW - CSF

KW - Imaging

KW - Neurotoxicity

KW - Neurotoxicity

UR - http://www.scopus.com/inward/record.url?scp=84952910839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952910839&partnerID=8YFLogxK

U2 - 10.1093/toxsci/kfv188

DO - 10.1093/toxsci/kfv188

M3 - Article

VL - 148

SP - 332

EP - 340

JO - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 2

M1 - kfv188

ER -